#ENSC

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology Ensysce Biosciences (NASDAQ:ENSC) announced the peer-reviewed publication of Phase 1 clinical data for PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose while preserving therapeutic opioid exposure.Findings show appropriate plasma levels at normal dosing and prevention of large opioid increases at supratherapeutic doses; MPAR received FDA Breakthrough designation in January 2024 and IP extends through 2042.

1 week ago

#ENSC Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 weeks ago

Original post on benzinga.com

Dow Dips Over 600 Points; US Producer Prices Increase In January US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in J...

#AAOI #EBS #ENSC #Equities #FLGT #Mid-Morning #Market #Update […]

[Original post on benzinga.com]

0 1 0 0

Stock Master

@stockmaster70.bsky.social

2 weeks ago

📢 Stocks Trending NOW: #NFLX #XYZ #DUOL #CRWV #DELL #PSKY #CAT #ENSC #MARA #ZS

0 0 0 0

1 month ago

#ENSC Expands its Global Patent Portfolio buff.ly/esg8xMl

0 0 0 0

Ensysce Biosciences Expands Global Opioid Patent Portfolio Ensysce Biosciences (NASDAQ:ENSC) announced on January 21, 2026 that the Brazilian Patent Office issued a Notice of Allowance for a patent (PI0919711-7) covering additional opioid families that use the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.The allowed patent includes both composition of matter and method of use claims, and the company says this expands its global intellectual property protection for next-generation analgesics, complementing existing allowances in North America, the EU, and South America. Management framed the development as strengthening its pain portfolio and advancing safer opioid formulations without compromising pain relief.

1 month ago

#ENSC Ensysce Biosciences Expands Global Opioid Patent Portfolio

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

New ADHD drug designed to deter abuse and overdose wins EU patent EU patent for PF8026 covers an amphetamine prodrug using TAAP and MPAR tech to cut abuse and overdose risks, as 3.9M people misused stimulants in 2023.

2 months ago

#ENSC Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Ensysce Biosciences Issues Annual Shareholder Letter Ensysce Biosciences (NASDAQ:ENSC) issued its 2025 annual shareholder letter outlining clinical, regulatory, IP and financing progress. Key 2025 achievements include initiation of the pivotal PF614-301 Phase 3 trial with enrollment started at two sites, FDA alignment on PF614 commercial manufacturing and CMC strategy, and advancement of PF614-MPAR under Breakthrough Therapy pathway. The company secured additional capital including a November 2025 $4M convertible preferred financing enabling access to up to $20M over 24 months and continued non-dilutive support from NIDA totaling over $25M for MPAR programs. A new MPAR patent allowance extends protection through 2042. Anticipated 2026 priorities include continued Phase 3 enrollment, further FDA interactions, MPAR labeling work, and PF9001 IND-enabling activities.

2 months ago

#ENSC Ensysce Biosciences Issues Annual Shareholder Letter

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

3 months ago

#ENSC Enrolls First Patient in Critical Phase 3 Trial buff.ly/4RnN2JO

0 0 0 0

3 months ago

#ENSC Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

3 months ago

#ENSC Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

3 months ago

#ENSC Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

3 months ago

#ENSC Bolsters Balance Sheet for Commercialization Push buff.ly/DetQGgv

0 0 0 0

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs Ensysce Biosciences (NASDAQ:ENSC) closed a $4.0 million convertible preferred financing on November 17, 2025, with the potential for up to an additional $16.0 million in future tranches over the next 24 months (up to $20.0 million total).The initial tranche carries a fixed conversion price of $2.50 per share, an alternate conversion based on average common stock prices, and 50% warrant coverage exercisable at the fixed conversion price for five years. Proceeds will accelerate the Phase 3 development of PF614 and support corporate initiatives, with management citing Phase 3 completion or market-readiness targets in the 18–24 month timeframe.

3 months ago

#ENSC Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Ensysce Biosciences Reports Third Quarter 2025 Financial Results Ensysce Biosciences (NASDAQ:ENSC) reported Q3 2025 results and operational milestones on November 14, 2025. Key developments include the initiation of the pivotal Phase 3 PF614-301 trial in July 2025, FDA Breakthrough Therapy designation support for PF614-MPAR, and engagement of Rho, Inc. to run the pivotal study.Financial highlights: cash $1.7M at Sept 30, 2025; completed a $4M convertible preferred stock financing in November with up to $16M additional tranches available; Q3 federal grant funding $0.5M (vs $3.4M a year ago); R&D $3.0M (Q3 2025) and net loss $3.7M (Q3 2025).

4 months ago

#ENSC Ensysce Biosciences Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 Ensysce Biosciences (NASDAQ:ENSC) released video highlights from its PAINWeek 2025 symposium titled "Pain Management, RE-Invented: A New Era for Analgesia", held in Las Vegas on September 3, 2025. The symposium featured medical and scientific leaders discussing challenges in pain treatment and Ensysce's proprietary platforms TAAP™ and MPAR®, which aim to reduce opioid misuse and overdose while preserving analgesia. Video highlights with expert commentary and real-world perspectives are available on the Ensysce Media/Science Center at www.ensysce.com.The company said it continues advancing its portfolio toward commercialization with the goal of safer severe-pain management.

5 months ago

#ENSC Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Standing-Room-Only: 400 Pain Experts Review Ensysce's Revolutionary Overdose-Proof Opioid Technology Ensysce's TAAP and MPAR technologies use body chemistry to control opioid release, preventing overdose. Phase 3 trial upcoming for PF614 in post-surgical pain management.

6 months ago

#ENSC Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Pain Medicine Innovation Leader: Ensysce CCO Birkett to Chair Major Product Planning Summit 2025 Geoff Birkett, Ensysce's CCO leading PF614 pain drug launch, will chair Fierce NPP Summit Sept 8-11 in Philadelphia. Former AstraZeneca SVP to present case study on product launches.

6 months ago

#ENSC Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

7 months ago

#ENSC Focused on Bringing Change to Pain Relief Market buff.ly/6VGR3kR

0 0 0 0

Novel Opioid with Built-in Overdose Protection Enters Final Testing Phase as Ensysce Secures Major Funding Pain therapy developer advances PF614 to Phase 3 trials, targeting safer opioid treatment with abuse deterrence. Receives $5.3M NIDA grant for overdose protection program. Learn more.

7 months ago

#ENSC Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Leading Indicators, Thursday July 31, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend with AROON Oscillator, Thu Jul 31st - #OSBC #NRIX #MODV #LOCO #KRT #INMD #HYPD #GYRE #FLGC #ENSC #TWST #DENN #CXDO #BWAY #ATEC #WSR #TYG #SQNS #OEC #MYE #LAW #SPT #KYX #IPI #HVT #GPRK #FINV - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

First-Ever Smart Opioid With Automatic Overdose Protection Gets FDA Green Light for Development Revolutionary pain medication combines TAAP and MPAR technologies to prevent overdose while maintaining effective relief. FDA supports expedited approval path. Learn more.

7 months ago

#ENSC Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

7 months ago

#ENSC Start Phase 3 Trial on Abuse-Resistant Pain Reliever buff.ly/G8jZFaP

0 0 0 0

FDA-Reviewed Phase 3 Trial Begins: Revolutionary Opioid Promises Pain Relief Without Abuse Risk FDA-reviewed Phase 3 study of PF614 targets post-surgical pain with built-in abuse protection. Rho Inc. partnership accelerates clinical development. Learn more.

7 months ago

#ENSC Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

FDA-Designated Breakthrough Pain Drug Advances: New Solution to Opioid Overdose Crisis Shows Promise Ensysce's PF614-MPAR achieves full enrollment in critical food effect study. Novel opioid combines pain relief with built-in overdose protection. See trial details.

8 months ago

#ENSC Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish moving average convergence divergence crossovers, Wed May 14th - #UNIT #TLS #SRDX #PAL #OMCL #LUCD #KGEI #GURE #ENSC #CLNN #BLUE #AUDC #VOC #UTZ #NCDL #KODK #CIA #ARIS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

10 months ago

#ENSC is Moving Closer to Changing the Pain Relief Market buff.ly/NbtyA8M

0 0 0 0

Ensysce Biosciences Reports First Quarter 2025 Financial Results Ensysce Biosciences (NASDAQ:ENSC) reported Q1 2025 financial results and significant developments in its opioid treatment programs. The company received a U.S. patent for PF9001, their lead opioid use disorder (OUD) drug candidate, adding to their portfolio of over 100 patents. They completed Part 1 of the PF614-MPAR-102 clinical study, demonstrating overdose protection capabilities. Financial highlights include: cash position of $3.1M as of March 31, 2025, federal grant funding of $1.3M (up from $0.3M YoY), and a net loss of $1.9M (improved from $3.1M loss in Q1 2024). R&D expenses increased to $1.9M from $0.8M YoY. The company plans to initiate Phase 3 trials for PF614 in mid-2025 and continues development of their TAAP and MPAR® technologies for safer opioid pain management solutions.

10 months ago

#ENSC Ensysce Biosciences Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ENSC/ensysce-biosci...

0 0 0 0